Dosage and administration In the VISIONARY trial, sibeprenlimab was administered SC at a dose of 400 mg every 4 weeks and can be self-administered. Place in therapy IgAN, also known as Berger’s...

Submitted supplemental drugs brensocatib oral Manufacturer: PTC Proposed indications Friedreich's ataxia (FA) Clinical overview Mechanism of action Vatiquinone is a first-in-class selective...

New resource page offers the latest GLP-1 insights, research and perspectives

In the latest episode of the “Pharmacy Friends” podcast, hear more from Prime Therapeutics experts about how oral glucagon-like peptide-1 (GLP-1) agonist medications may transform the treatment...

New report details the latest on GLP-1s

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

publications Spring 2025 Prime Therapeutics Report March 21, 2025 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 18)...

Maryam Tabatabai, PharmD, associate vice president of clinical information, offers predictions about forthcoming drug approvals, the latest on a new voucher pilot, updated biosimilar guidance and more

Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes